Activated Sites
| CHLA | UCSF | |
| Cincinnati | Children's National | |
| MSKCC | Seattle | |
| Indiana Riley | Utah | |
| Phoenix Children's | Johns Hopkins | |
| C.S. Mott Michigan | Chicago Lurie | |
| St. Jude | CHOP | |
| Miami | Colorado | |
| Atlanta |
Children's Mercy |
|
| OHSU | Levine Children's Hospital | |
| UTSW |
Reliance Packet Status
|
Site |
Assigned TACL Coordinator/Site activated |
Site Coordinator(s) | Type of submission | CHLA IRB Reliance Packet Status | Date of Submisison to CHLA IRB (Target or actual)* | Pending Issues During Review and Start up | |
| Wisconsin | Liz (In Training) Suganya | Resubmission | Approved but requires resubmission | Target August 2026 | Pending site IRB acknowledgment, study start up and regulatory documents | ||
| Ohio-Nationwide | Suganya | New Submission | In progress | Approved(3.11.2026) | |||
| Carolinas | Suganya |
Site Activated |
|||||
| UTSW | Suganya |
Site Activated |
|||||
| CNMC | Suganya | Approved | |||||
| DFCI | Suganya | New Submission | Approved 8/21/2026 |
6/12/2026
|
Original (12/29/25) |
||
| Cook | Ellynore | New Submission | In progress | TBD | |||
| Washington Univeresity St. Louis | Ellynore | Suzi Cooper | New submission | Review of consents | TBD | ||
| Atlanta | Liz |
Melissa Schink Risa Bernard |
Resubmission of Assent/Consent | Not started |
Target - August 2026 |
||
| Miami | Liz | Resubmission - spanish consent translation | Not started | Target - August 2026 | |||
| St. Jude | Liz | Lora Blann | Resubmission - spanish consent translation | Not Started | early- August 2026 | ||
Following pre-review approval by TACL Ops, please submit to your local IRB and confirm acceptance. This local IRB approval is required prior to submission to the CHLA IRB. Resubmission of the consent will not be prioritized over other site submissions.
If your site is not listed and your site plans to participate it will be 1-2 months before your site will be submitted.
Do not send your documents to TACL Ops unless you are one of the siites in progress listed above.
All sites that have expressed an interest in this trial have been prioritized. If your site has a potential patient, this will impact prioritization and please contact tacl@chla.usc.edu and Dr. Elliot Stieglitz (Study Chair)
*Protocol Amendment #2 will be submitted in September 2026